Y-Intercept (HK)’s Nurix Therapeutics NRIX Stock Holding History

Y-Intercept (HK)’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.67M	Buy	192,434 +137,296	+249%	+$2.34M	0.09%	302
2026 Q1	$855K	Buy	+55,138	New	+$914K	0.02%	1091
2025 Q4	–	Sell	-55,231	Closed	-$510K	–	1862
2025 Q3	$510K	Buy	+55,231	New	+$574K	0.01%	1252
2025 Q2	–	Sell	-31,458	Closed	-$374K	–	1896
2025 Q1	$374K	Buy	+31,458	New	+$526K	0.03%	827
2024 Q4	–	Sell	-15,388	Closed	-$346K	–	1507
2024 Q3	$346K	Buy	+15,388	New	+$349K	0.02%	949

Other funds holding NRIX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Torren Management San Diego, California $197M AUM

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Y-Intercept (HK)'s NRIX Position: Q2 2026 in Review

Y-Intercept (HK) increased its Nurix Therapeutics (NRIX) stake by 249% in Q2 2026, buying an estimated $2.34M and bringing the position to 192,434 shares worth $4.67M. The position accounts for 0.09% of the portfolio, ranked #302.

Y-Intercept (HK) first reported a position in NRIX in Q3 2024 and has held it in 5 quarters since. 10 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Y-Intercept (HK) held 192,434 shares of Nurix Therapeutics worth $4.67M as of Q2 2026.
Y-Intercept (HK) bought 137,296 Nurix Therapeutics shares in Q2 2026, an estimated $2.34M.
Nurix Therapeutics made up 0.09% of Y-Intercept (HK)'s portfolio in Q2 2026, its #302 holding.
Y-Intercept (HK) first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 5 quarters since.
10 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.